Overview

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
HonorHealth Research Institute
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Gemcitabine
Paclitaxel